Viking Therapeutics ( VKTX -0.30%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Viking Therapeutics (VKTX) announced that it has signed a broad, multi-year manufacturing agreement with CordenPharma, a contract development ...

The company expects to roll out a final-phase VK2735 for obesity and diabetes patients sometime in the second quarter of 2025. An oral version of the drug is set for a three-month test later in 2025.

In this post-pandemic world, it’s surprisingly (and frustratingly) rare to find a new car for under $30,000. Various factors are responsible, including emissions rules and the inexorable popularity of ...

Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance accuracy, reproducibility, and efficiency in cell manufacturing. Astellas ...

In the MAD trial, oral VK2735 also demonstrated encouraging safety and tolerability through 28 days of once-daily dosing at doses up to and including 100 mg. The majority (99%) of observed ...

Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 1 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone ...